Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial | Substance Use and Addiction Medicine | JAMA Psychiatry | JAMA Network What the evidence suggests: Low doses of Semaglutide may reduce addictive behaviors in adults with alcohol use disorder
Key Areas of Research: Endocrine: Growth hormone, IGF-1, signaling Metabolic: Lipids, lean tissue, glucose balance Cellular: Proliferation, repair, recovery Systemic: Cardiovascular, viability, healing Together, these findings suggest broad experimental potential for CJC-1295 and Ipamorelin across multiple biological pathways
The peroxisome proliferator-activated receptor - agonist gemfibrozil promotes defense against mycobacterium abscessus infections
tesamorelin is reserved for patients with stronger clinical indications
The Recycling Connection There is an even deeper connection between the two